Nabi Biopharmaceuticals · Rockville, MD United States (NASDAQ: NABI)
| 12276 Wilkins Ave. | Phone: 301-770-3099 |
| Rockville, MD | Fax: 301-770-3097 |
| 20852 | Toll Free: 800-685-5579 |
| United States | 
Map This Company |
Nabi Biopharmaceuticals Rankings
More Companies in These Related Industries: Company Description
Nabi Biopharmaceuticals nabs human antibodies to make pharmaceutical therapies. The biotechnology company develops vaccine products for conditions in a number of areas, including infectious diseases and nicotine addiction. Its primary candidate, the NicVAX vaccine for nicotine addition, works by stimulating antibodies (immune-system proteins) that reduce cravings. NicVAX is being developed in partnership with
Nabi Biopharmaceuticals Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: NABI Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 35 |
Executives
33 executives listed for Nabi Biopharmaceuticals's Rockville, MD location.
| Chairman | Geoffrey Cox | |
|---|---|---|
| President, CEO, Acting CFO, and Director | Raafat Fahim | |
| SVP Strategic Planning and Business Operations | Matthew Kalnik |